Adaptive Biotechnologies Officer & Director Files Intent to Sell $6.8M in Stock
Summary
An Officer and Director of Adaptive Biotechnologies has filed a Form 144 to sell approximately $6.8 million worth of stock, continuing a pattern of significant insider selling.
Key Events
-
Officer & Director Files Intent to Sell
Chad M. Robins, an Officer and Director, filed a Form 144 to sell 470,167 shares of common stock, valued at approximately $6.8 million.
-
Follows Recent Vesting
The shares intended for sale were acquired upon the vesting of restricted stock units and performance stock units on March 4, 2026.
-
Part of Ongoing Insider Distribution
This proposed sale adds to a pattern of significant insider selling by Robins, who has already sold over $12.5 million in shares in the past three months. The company has seen over $32 million in net insider selling across all insiders in the last 90 days.
Analysis
Chad M. Robins, an Officer and Director of Adaptive Biotechnologies, has filed a Form 144 indicating an intent to sell 470,167 shares of common stock, valued at approximately $6.8 million. This proposed sale follows the recent vesting of restricted stock units and performance stock units. This transaction is part of a broader pattern of significant insider distribution, with Robins having sold over $12.5 million in shares in the past three months, contributing to a total net insider selling of over $32 million across the company in the last 90 days. While often related to liquidity or tax planning, a substantial and ongoing selling trend by a key executive can be perceived negatively by investors, especially following the company's recent positive financial results.
At the time of this filing, ADPT was trading at $13.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.68 to $20.76. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.